These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 398417)

  • 1. Glomerular deposition of complement-control proteins in acute and chronic glomerulonephritis.
    Wyatt RJ; McAdams AJ; Forristal J; Snyder J; West CD
    Kidney Int; 1979 Oct; 16(4):505-12. PubMed ID: 398417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III.
    West CD; McAdams AJ
    Am J Kidney Dis; 1998 Mar; 31(3):427-34. PubMed ID: 9506679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membranoproliferative glomerulonephritis type III: association of glomerular deposits with circulating nephritic factor-stabilized convertase.
    West CD; McAdams AJ
    Am J Kidney Dis; 1998 Jul; 32(1):56-63. PubMed ID: 9669425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of complement activation in membranous and membranoproliferative glomerulonephritis.
    Moseley HL; Whaley K
    Kidney Int; 1980 Apr; 17(4):535-44. PubMed ID: 6446614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum terminal complement component levels in hypocomplementemic glomerulonephritides.
    Clardy CW; Forristal J; Strife CF; West CD
    Clin Immunol Immunopathol; 1989 Mar; 50(3):307-20. PubMed ID: 2917423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
    Hiramatsu M; Balow JE; Tsokos GC
    J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membranoproliferative glomerulonephritis. Localization of early components of complement in glomerular deposits.
    Davis BK; Cavallo T
    Am J Pathol; 1976 Aug; 84(2):283-98. PubMed ID: 133617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of in vitro activation of guinea pig complement in glomeruli of human renal biopsy materials from varied subtypes of glomerulonephritis.
    Masugi Y; Kogoshi T; Ishizaki M
    Acta Pathol Jpn; 1980 Nov; 30(6):995-1007. PubMed ID: 7446122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for glomerular modulation of complement activation.
    Moseley HL; Whaley K
    J Clin Lab Immunol; 1979 Apr; 2(1):9-13. PubMed ID: 95813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The quest for an intrinsic C3 activating factor in human glomerular disease.
    Roberts JL; Lewis EJ
    Surv Immunol Res; 1982; 1(2):191-8. PubMed ID: 6227068
    [No Abstract]   [Full Text] [Related]  

  • 12. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement fixation in acute serum sickness: assembly of glomerular-bound C3-convertase.
    Bartolotti SR; Peters DK
    Clin Exp Immunol; 1979 Sep; 37(3):391-8. PubMed ID: 389495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III.
    Varade WS; Forristal J; West CD
    Am J Kidney Dis; 1990 Sep; 16(3):196-206. PubMed ID: 2205097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classical complement pathway activation in membranoproliferative glomerulonephritis.
    Ooi YM; Vallota EH; West CD
    Kidney Int; 1976 Jan; 9(1):46-53. PubMed ID: 781380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
    Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
    Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The alternative pathway C3 convertase and glomerular deposits.
    West CD; McAdams AJ
    Pediatr Nephrol; 1999 Jun; 13(5):448-53. PubMed ID: 10412868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement activation in renal disease.
    West CD
    Uremia Invest; 1984-1985; 8(3-4):225-35. PubMed ID: 6545495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Studies of complement, nephritic factor, and circulating immune complexes in chronic mesangiocapillary glomerulonephritis types I and II (author's transl)].
    Mirapeix E; Yagüe J; Vives J; Revert L
    Med Clin (Barc); 1981 Jun; 77(1):21-6. PubMed ID: 7253758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences between membranoproliferative glomerulonephritis types I and III in clinical presentation, glomerular morphology, and complement perturbation.
    Jackson EC; McAdams AJ; Strife CF; Forristal J; Welch TR; West CD
    Am J Kidney Dis; 1987 Feb; 9(2):115-20. PubMed ID: 3826060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.